tetano
Editor, Senior Moderator
Nature
. 2020 Jul 30.
doi: 10.1038/s41586-020-2607-z. Online ahead of print.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Noe B Mercado[SUP] 1 [/SUP], Roland Zahn[SUP] 2 [/SUP], Frank Wegmann[SUP] 2 [/SUP], Carolin Loos[SUP] 3 4 [/SUP], Abishek Chandrashekar[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Jinyan Liu[SUP] 1 [/SUP], Lauren Peter[SUP] 1 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 1 [/SUP], Xuan He[SUP] 1 [/SUP], David R Martinez[SUP] 5 [/SUP], Lucy Rutten[SUP] 2 [/SUP], Rinke Bos[SUP] 2 [/SUP], Danielle van Manen[SUP] 2 [/SUP], Jort Vellinga[SUP] 2 [/SUP], Jerome Custers[SUP] 2 [/SUP], Johannes P Langedijk[SUP] 2 [/SUP], Ted Kwaks[SUP] 2 [/SUP], Mark J G Bakkers[SUP] 2 [/SUP], David Zuijdgeest[SUP] 2 [/SUP], Sietske K Rosendahl Huber[SUP] 2 [/SUP], Caroline Atyeo[SUP] 3 6 [/SUP], Stephanie Fischinger[SUP] 3 6 [/SUP], John S Burke[SUP] 3 [/SUP], Jared Feldman[SUP] 3 6 [/SUP], Blake M Hauser[SUP] 3 6 [/SUP], Timothy M Caradonna[SUP] 3 6 [/SUP], Esther A Bondzie[SUP] 1 [/SUP], Gabriel Dagotto[SUP] 1 6 [/SUP], Makda S Gebre[SUP] 1 6 [/SUP], Emily Hoffman[SUP] 1 [/SUP], Catherine Jacob-Dolan[SUP] 1 6 [/SUP], Marinela Kirilova[SUP] 1 [/SUP], Zhenfeng Li[SUP] 1 [/SUP], Zijin Lin[SUP] 1 [/SUP], Shant H Mahrokhian[SUP] 1 [/SUP], Lori F Maxfield[SUP] 1 [/SUP], Felix Nampanya[SUP] 1 [/SUP], Ramya Nityanandam[SUP] 1 [/SUP], Joseph P Nkolola[SUP] 1 [/SUP], Shivani Patel[SUP] 1 [/SUP], John D Ventura[SUP] 1 [/SUP], Kaylee Verrington[SUP] 1 [/SUP], Huahua Wan[SUP] 1 [/SUP], Laurent Pessaint[SUP] 7 [/SUP], Alex Van Ry[SUP] 7 [/SUP], Kelvin Blade[SUP] 7 [/SUP], Amanda Strasbaugh[SUP] 7 [/SUP], Mehtap Cabus[SUP] 7 [/SUP], Renita Brown[SUP] 7 [/SUP], Anthony Cook[SUP] 7 [/SUP], Serge Zouantchangadou[SUP] 7 [/SUP], Elyse Teow[SUP] 7 [/SUP], Hanne Andersen[SUP] 7 [/SUP], Mark G Lewis[SUP] 7 [/SUP], Yongfei Cai[SUP] 8 [/SUP], Bing Chen[SUP] 8 9 [/SUP], Aaron G Schmidt[SUP] 3 6 9 [/SUP], R Keith Reeves[SUP] 1 [/SUP], Ralph S Baric[SUP] 5 [/SUP], Douglas A Lauffenburger[SUP] 4 [/SUP], Galit Alter[SUP] 3 9 [/SUP], Paul Stoffels[SUP] 2 [/SUP], Mathai Mammen[SUP] 2 [/SUP], Johan Van Hoof[SUP] 2 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Dan H Barouch[SUP] 10 11 12 13 [/SUP]
Affiliations
Abstract
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic[SUP]1-8[/SUP]. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes[SUP]9,10[/SUP]. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
. 2020 Jul 30.
doi: 10.1038/s41586-020-2607-z. Online ahead of print.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Noe B Mercado[SUP] 1 [/SUP], Roland Zahn[SUP] 2 [/SUP], Frank Wegmann[SUP] 2 [/SUP], Carolin Loos[SUP] 3 4 [/SUP], Abishek Chandrashekar[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Jinyan Liu[SUP] 1 [/SUP], Lauren Peter[SUP] 1 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 1 [/SUP], Xuan He[SUP] 1 [/SUP], David R Martinez[SUP] 5 [/SUP], Lucy Rutten[SUP] 2 [/SUP], Rinke Bos[SUP] 2 [/SUP], Danielle van Manen[SUP] 2 [/SUP], Jort Vellinga[SUP] 2 [/SUP], Jerome Custers[SUP] 2 [/SUP], Johannes P Langedijk[SUP] 2 [/SUP], Ted Kwaks[SUP] 2 [/SUP], Mark J G Bakkers[SUP] 2 [/SUP], David Zuijdgeest[SUP] 2 [/SUP], Sietske K Rosendahl Huber[SUP] 2 [/SUP], Caroline Atyeo[SUP] 3 6 [/SUP], Stephanie Fischinger[SUP] 3 6 [/SUP], John S Burke[SUP] 3 [/SUP], Jared Feldman[SUP] 3 6 [/SUP], Blake M Hauser[SUP] 3 6 [/SUP], Timothy M Caradonna[SUP] 3 6 [/SUP], Esther A Bondzie[SUP] 1 [/SUP], Gabriel Dagotto[SUP] 1 6 [/SUP], Makda S Gebre[SUP] 1 6 [/SUP], Emily Hoffman[SUP] 1 [/SUP], Catherine Jacob-Dolan[SUP] 1 6 [/SUP], Marinela Kirilova[SUP] 1 [/SUP], Zhenfeng Li[SUP] 1 [/SUP], Zijin Lin[SUP] 1 [/SUP], Shant H Mahrokhian[SUP] 1 [/SUP], Lori F Maxfield[SUP] 1 [/SUP], Felix Nampanya[SUP] 1 [/SUP], Ramya Nityanandam[SUP] 1 [/SUP], Joseph P Nkolola[SUP] 1 [/SUP], Shivani Patel[SUP] 1 [/SUP], John D Ventura[SUP] 1 [/SUP], Kaylee Verrington[SUP] 1 [/SUP], Huahua Wan[SUP] 1 [/SUP], Laurent Pessaint[SUP] 7 [/SUP], Alex Van Ry[SUP] 7 [/SUP], Kelvin Blade[SUP] 7 [/SUP], Amanda Strasbaugh[SUP] 7 [/SUP], Mehtap Cabus[SUP] 7 [/SUP], Renita Brown[SUP] 7 [/SUP], Anthony Cook[SUP] 7 [/SUP], Serge Zouantchangadou[SUP] 7 [/SUP], Elyse Teow[SUP] 7 [/SUP], Hanne Andersen[SUP] 7 [/SUP], Mark G Lewis[SUP] 7 [/SUP], Yongfei Cai[SUP] 8 [/SUP], Bing Chen[SUP] 8 9 [/SUP], Aaron G Schmidt[SUP] 3 6 9 [/SUP], R Keith Reeves[SUP] 1 [/SUP], Ralph S Baric[SUP] 5 [/SUP], Douglas A Lauffenburger[SUP] 4 [/SUP], Galit Alter[SUP] 3 9 [/SUP], Paul Stoffels[SUP] 2 [/SUP], Mathai Mammen[SUP] 2 [/SUP], Johan Van Hoof[SUP] 2 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Dan H Barouch[SUP] 10 11 12 13 [/SUP]
Affiliations
- PMID: 32731257
- DOI: 10.1038/s41586-020-2607-z
Abstract
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic[SUP]1-8[/SUP]. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes[SUP]9,10[/SUP]. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.